Expertise in
9
conditions

Dr. Viralkumar K. Bhanderi

Oncology
Florida Cancer Specialists & Research Institute - TLC
2351 Phillips Rd, 
Tallahassee, FL 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Expertise in
9
conditions
Florida Cancer Specialists & Research Institute - TLC
2351 Phillips Rd, 
Tallahassee, FL 

Overview

Viralkumar Bhanderi is an Oncologist practicing medicine in Tallahassee, Florida.

Dr. Bhanderi is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Richter Syndrome, and Colorectal Cancer.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 14 clinical trials. Dr. Bhanderi is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in FL

Hospital Affiliations

Tallahassee Memorial Healthcare
Hca Florida Capital Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Florida Cancer Specialists & Research Institute - TLC
2351 Phillips Rd, Tallahassee, FL 32308
Other Locations
Florida Cancer Specialists & Research Institute - LCO
795 SW State Road 47, Lake City, FL 32025

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Enrollment Status: Recruiting
Publish Date: September 01, 2026
Intervention Type: Drug
Study Drugs: Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Trastuzumab and Pertuzumab, Vemurafenib and Cobimetinib, Regorafenib, Olaparib, Pembrolizumab, Nivolumab and Ipilimumab, Abemaciclib, Afatinib, Talazoparib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Entrectinib, Larotrectinib, Tucatinib plus Trastuzumab Subcutaneous (SC)
Study Phase: Phase 2
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Drug: APL-101
Study Phase: Phase 2
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
Enrollment Status: Active_not_recruiting
Publish Date: August 18, 2026
Intervention Type: Drug, Other
Study Drug: Ribociclib
Study Phase: Phase 3
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: June 15, 2026
Intervention Type: Drug
Study Drugs: Zimberelimab, Domvanalimab, Etrumadenant
Study Phase: Phase 2
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2026
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Venetoclax, Rituximab
Study Phase: Phase 3
A Phase II Study of Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Who Have Had Prior Treatment With a PD-1 Inhibitor
A Phase II Study of Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Who Have Had Prior Treatment With a PD-1 Inhibitor
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Etrumadenant, Zimberelimab, AB680, Enzalutamide, Docetaxel
Study Phase: Phase 1/Phase 2
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 3
View 8 Less Clinical Trials

3 Total Publications

ChatGPT's role in the rapidly evolving hematologic cancer landscape.
ChatGPT's role in the rapidly evolving hematologic cancer landscape.
Journal: Future science OA
Published: September 03, 2025
Similar Doctors
Expertise in
39
conditions
Dr. Scott M. Bradfield
Hematology | Oncology
Expertise in
39
conditions
Dr. Scott M. Bradfield
Hematology | Oncology
Referral may be required

Nemours Children's Health, Tallahassee

2418 E. Plaza Drive, 
Tallahassee, FL 
 (0.3 miles away)
904-697-3600
Languages Spoken:
English
See accepted insurances
Accepting New Patients

"I’m a pediatric oncologist (cancer specialist) based at the Nemours Children’s Specialty Care, Jacksonville. I’m a triathlete, married with three children, with an interest in finding ways to constantly improve cancer care for children. We returned to Florida, my home state, after travelling the country to complete my medical training. While I was growing up, my mother worked in an OB/GYN office, so I always said I wanted to do the same """"because I love to work with kids."""" At that time, nobody explained to me that OB/GYNs treat women and it’s really pediatricians who treat kids. By medical school, it was clear pediatrics was what I was interested in. I love the personal interactions with families during some of their happiest and also most difficult times. I find the clinical aspects and science behind oncology fascinating. I specialize in cancer care for children and try to find ways to improve the care they receive. I am currently leading the expansion of our treatment protocols for relapsed disease so patients can have more aggressive options if their cancer returns.". Dr. Bradfield is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma, Langerhans Cell Histiocytosis, and Bone Marrow Aspiration. Dr. Bradfield is board certified in American Board Of Pediatrics. Dr. Bradfield is currently accepting new patients.

Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required

Tallahassee Memorial Healthcare Inc.

1775 One Healing Pl, 
Tallahassee, FL 
 (0.7 miles away)
850-431-5360
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Carolyn Johnston is an Oncologist practicing medicine in Tallahassee, Florida. Dr. Johnston is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Malignant Mixed Mullerian Tumor, Endometrial Cancer, Vulvar Cancer, and Sertoli-Leydig Cell Tumor. Dr. Johnston is currently accepting new patients.

Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Tmh Physician Partners-Cancer & Hematology

1775 One Healing Pl # 2, 
Tallahassee, FL 
 (1.5 miles away)
850-431-5360
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tim Broeseker is an Oncologist practicing medicine in Tallahassee, Florida. Dr. Broeseker is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), ALK-Positive Non-Small Cell Lung Cancer, Lung Adenocarcinoma, Squamous Cell Lung Carcinoma, and Bone Marrow Aspiration. Dr. Broeseker is currently accepting new patients.

Frequently Asked Questions about Dr. Viralkumar K. Bhanderi

How do I make an appointment with Dr. Viralkumar K. Bhanderi?

You can book an appointment with Dr. Viralkumar K. Bhanderi by calling their office at 850-279-1427. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Viralkumar K. Bhanderi a top-rated expert for Chronic Lymphocytic Leukemia (CLL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Viralkumar K. Bhanderi is classified as an Advanced expert for Chronic Lymphocytic Leukemia (CLL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Viralkumar K. Bhanderi specialize in?

While Dr. Viralkumar K. Bhanderi is a Oncology, they have specific expertise in Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), and Richter Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Viralkumar K. Bhanderi participate in research or clinical trials?

Yes. Dr. Viralkumar K. Bhanderi has published 3 articles and abstracts on conditions like Chronic Lymphocytic Leukemia (CLL). You can view a list of Dr. Viralkumar K. Bhanderi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Viralkumar K. Bhanderi accept my insurance?

Dr. Viralkumar K. Bhanderi accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 850-279-1427 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bhanderi's expertise for a condition
ConditionClose
      View All 9 Advanced Conditions
      View All 29 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile